Advertisement

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Published:October 08, 2018DOI:https://doi.org/10.1016/j.ygyno.2018.10.001

      Highlights

      • Elesclomol increases reactive oxygen species and enhances the efficacy of chemotherapy in preclinical models.
      • There is no added clinical benefit to paclitaxel when elesclomol is added to treatment of recurrent ovarian cancer.
      • The combination of paclitaxel and elesclomol is well tolerated.

      Abstract

      Objective

      Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovarian, tubal or peritoneal cancer through the frequency of objective tumor responses (ORR).

      Methods

      Patients with measurable disease, acceptable organ function, performance status ≤ 2, and one prior platinum containing regimen were eligible. A two-stage design was utilized with a target sample size of 22 and 30 subjects, respectively. Prior Gynecologic Oncology Group studies within the same population involving single agent taxanes showed an ORR of approximately (20%) and served as a historical control for direct comparison. The present study was designed to determine if the regimen had an ORR of ≥40% with 90% power.

      Results

      Fifty-eight patients were enrolled, of whom 2 received no study treatment and were inevaluable. The median number of cycles was 3 (268 total cycles, range 1–18). The number of patients responding was 11 (19.6%; 90% CI 11.4% to 30.4%) with one complete response. The median progression-free survival and overall survival was 3.6 months and 13.3 months, respectively. The median ORR duration was 9.2 months. Percentages of subjects with grade 3 toxicity included: Neutropenia 9%; anemia 5%; metabolic 5%; nausea 4%; infection 4%; neurologic (mostly neuropathy) 4%; and vascular (mostly thromboembolism) 4%. There were no grade 4 toxicities reported.

      Conclusions

      This combination was well tolerated but is unworthy of further investigation based on the proportion responding [ClinicalTrials.gov Identifier: NCT00888615].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Coleman R.L.
        • Monk B.J.
        • Sood A.K.
        • Herzog T.J.
        Latest research and treatment of advanced-stage epithelial ovarian cancer.
        Nat. Rev. Clin. Oncol. 2013; 10: 211-224
        • Rose P.G.
        • Blessing J.A.
        • Ball H.G.
        • Hoffman J.
        • Warshal D.
        • Degeest K.
        • et al.
        A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2003; 88: 130-135
        • Markman M.
        • Blessing J.
        • Rubin S.C.
        • Connor J.
        • Hanjani P.
        • Waggoner S.
        Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2006; 101: 436-440
        • Coleman R.L.
        • Brady W.
        • McMeekin D.S.
        • Rose P.G.
        • Soper J.T.
        • Lentz S.S.
        • Hoffman J.S.
        • Shahin M.S.
        A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group (GOG) study.
        J. Clin. Oncol. 2010; 28 (suppl; abstr 5010): 7s
        • Sabbatini P.
        • Sill M.W.
        • O'Malley D.
        • Adler L.
        • Secord A.A.
        A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2008; 111: 455-460
        • Herzog T.J.
        • Monk B.J.
        Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?.
        Gynecol. Oncol. Res. Pract. 2017; 4: 13
        • Hasinoff B.B.
        • Wu X.
        • Yadav A.A.
        • Patel D.
        • Zhang H.
        • Wang D.S.
        • et al.
        Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II).
        Biochem. Pharmacol. 2015; 93: 266-276
        • O'Day S.J.
        • Eggermont A.M.
        • Chiarion-Sileni V.
        • Kefford R.
        • Grob J.J.
        • Mortier L.
        • et al.
        Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
        J. Clin. Oncol. 2013; 20: 1211-1218
        • Gehrmann M.
        Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70.
        Curr. Opin. Investig. Drugs. 2006; 7: 574-580
        • Berkenblit A.
        • Eder Jr., J.P.
        • Ryan D.P.
        • Seiden M.V.
        • Tatsuta N.
        • Sherman M.L.
        • et al.
        Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
        Clin. Cancer Res. 2007; 13: 584-590
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1).
        Eur. J. Cancer. 2009; 45: 228-247
      1. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010).
        • Simon R.
        Optimal 2-stage trial design for phase II trials.
        Control. Clin. Trials. 1989; 10: 1-10
        • Chen T.T.
        • Ng T.H.
        Optimal flexible designs in phase II clinical trials.
        Stat. Med. 1998; 17: 2301-2312
        • Pujade-Lauraine E.
        • Hilpert F.
        • Weber B.
        • Reuss A.
        • Poveda A.
        • Kristensen G.
        • et al.
        Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.
        J. Clin. Oncol. 2014; 32: 1302-1308